Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training

What Was Tested

This registered not phased trial tested NAD+.

It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers.

Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis.

It had three arms (groups): one (experimental), one (experimental) and one (no intervention).

The registry classes the interventions as dietary supplement.

Who Took Part

16 planned participants were the target.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Over 18 years old. BMI \<30 kg/m2.

The full record lists 2 inclusion and 3 exclusion criteria; among the exclusions: present of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders; currently taking vitamin b supplements and/or nad precursors; taking medication that may affect the test results.

How the Study Was Run

The set-up was randomized, crossover and double-blind.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between NAD+ and the comparison at some point, usually with a gap in between.

As a double-blind NAD+ study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and outcomes assessor.

It started in 2026-01-06 with completion listed for 2027-07.

It ran at 1 site in China.

Its stated primary purpose is other.

What Was Measured

Researchers chose this as the main measure: Substrate utilization (CHO and fat oxidation rate) (time frame: From enrollment to the end of treatment at 4 weeks).

It also tracked 9 secondary outcomes, for example Oxygen consumption, Heart rate, Blood glucose concentration, Blood lactate concentration, Peak power output and Mean power output.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 16 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.